ADAM10 is expressed at elevated levels in numerous malignant tumors, including glioblastoma, breast cancer, oral squamous cell carcinoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma, and its excessive expression is correlated with poor prognosis and distant metastasis in tumor patients 4. Here, ADAM10 is linked to AL amyloidosis.